Table 2 Comparison of COVID19 and non-infection groups among AIRD patients on background therapy with tofacitinib

Age in years

51.5 ± 12.73

48.28 ± 11.96

NS^#

Gender M (F)

10 (26)

55 (244)

NS^*

1.71 (0.78–3.74)

Duration of AIRD in months

 < 24 Months

5 (13.89%)

55 (18.39%)

0.34^$

0.72 (0.27–1.92)

 ≥ 24 Months

31 (86.11%)

244 (81.61%)

Smoking

0

5 (1.67%)

NS^$

-

DM

9 (25.0%)

34 (11.37%)

0.04^*

2.60 (1.13–5.99)

HTN

11 (30.56%)

60 (20.07%)

NS^*

1.75 (0.82–3.76)

Obesity BMI > 30

3 (8.33%)

8 (2.68%)

NS^$

3.34 (0.84–13.08)

Asthma/ILD

2 (5.56%)

7 (2.34%)

NS^$

4.22 (1.38–12.94)

Diagnosis

 RA

25 (69.44%)

221 (73.91%)

< 0.0001*

0.8 (0.38–1.71)

 PsA

4 (11.11%)

25 (8.36%)

< 0.0001$

1.37 (0.45–4.19)

 SpA

6 (16.67%)

29 (9.7%)

NS^*

1.86 (0.72–4.85)

 Others

1 (2.78%)

24 (8.03%)

NS^$

0.33 (0.04–2.50)

Hospitalization

10 (27.78%)

0

NA

-

Medications

ACEi

0

2 (0.67%)

NS^$

-

ARB

5 (13.89%)

14 (4.68%)

NS^$

3.28 (1.11–9.73)

Glucocorticoid

13 (36.11%)

137 (45.82%)

NS^*

0.67 (0.33–1.37)

Methotrexate

19 (52.78%)

212 (70.9%)

0.04^*

0.46 (0.23–0.92)

HCQ

7 (19.44%)

105 (35.12%)

NS^*

-

Leflunomide

5 (13.89%)

43 (14.38%)

NS^$

0.96 (0.35–2.61)

Apremilast

0

2 (0.67%)

NS^$

-

Iguratimod

1 (2.78%)

1 (0.33%)

NS^$

8.51 (0.52-139.61)

Sulfasalazine

3 (8.33%)

9 (3.01%)

NS^$

2.93 (0.76–11.36)

Aspirin

1 (2.78%)

1 (0.33%)

NS^$

8.51 (0.52-139.61)

Anticoagulants

0

1 (0.33%)

NS^$

-

Other Drugs

18 (50.0%)

157 (52.51%)

NS^*

0.9 (0.45–1.81)

Vaccination status

COVID-19 vaccination

5 (13.89%)

156 (52.17%)

< 0.0001^*

0.15 (0.06–0.39)